Infectious disease. The case for deemphasizing genomics in malaria control.
Solving the enormous problem of malaria worldwide will require a balance between investments in research and control. In this point-counterpoint, two scientists describe the rationales for these very different strategies. Steve Hoffman believes that genomics research is the best investment in the future if we have the vision of malaria eradication. Chris Curtis presents an opposing viewpoint, that low-tech control approaches are the practical ones under current conditions.
Curtis
C F
CF
London School of Hygiene & Tropical Medicine, London WC1E 7HT, U.K. chris.curtis@lshtm.ac.uk
D000818:Animals; D030801:Animals, Genetically Modified; D000852:Anopheles / Q000235:genetics* / Q000469:parasitology; D000962:Antimalarials / Q000494:pharmacology / Q000627:therapeutic use; D017344:Genes, Insect; D017125:Genes, Protozoan; D023281:Genomics; D006801:Humans; D007303:Insect Vectors / Q000235:genetics / Q000469:parasitology; D007306:Insecticides; D008288:Malaria / Q000188:drug therapy / Q000469:parasitology / Q000517:prevention & control* / Q000635:transmission; D017780:Malaria Vaccines; D009032:Mosquito Control; D010572:Pest Control, Biological; D010961:Plasmodium / Q000235:genetics*; D012106:Research
D000962:Antimalarials; D007306:Insecticides; D017780:Malaria Vaccines